1.
Acta Pharmaceutica Sinica B
; (6): 1315-1328, 2021.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-881201
ABSTRACT
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl
